Published in Lancet Neurol on August 10, 2020
Factors affecting relapse rate in patients with neuromyelitis optica spectrum disorder - Authors' reply. Lancet Neurol (2020) 0.75
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2020) 3.93